Anyplex™BRAF V600E Real-time Detection

Detection of BRAF V600E Mutation



Anyplex™ BRAF V600E Real-time Detection is designed to detect BRAF mutation (V600E) characteristic of papillary thyroid carcinoma from samples of thyroid tissue, fine needle aspiration biopsy (FNAB), H&E slides and paraffin-embedded tissues. The BRAF gene is involved in mediating cellular response to growth, differentiation and death signals in RAS → RAF → MEK → MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1) 2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26 – 69% (45-50 % on average) of all cases1) 3).

1. M Xing. BRAF mutation in thyroid cancer, Endocrine-Related Cancer, 2005, 12, 245-262.
2. Wojciechowska K and Lewinski A: BRAF Mutations in Papillary Thyroid Carcinoma, Endocrine Regulations, 2006, 40, 129-138.
3. Ki-wook Chung et al. Clinical Endocrinology, 2006, 65, 660-666.


  1. BRAF gene mutation test in various clinical samples
  2. Detection limit : 1% of BRAF gene mutation
  3. Short TAT : less than 2 hours (after extraction)
  4. Use Human β- globin as a Heterologous internal control
  5. Broad range of usable DNA template: Concentration measurements without inspection
  6. Quick and easy data interpretation by Seegene viewer software


- V600E  


- Thyroid tissues
- Thyroid fine needle aspiration biopsy (FNAB)
- Formalin fixed paraffin embedded (FFPE) thyroid
- Hematoxylin and eosin (H&E) thyroid slide
- Liquid based cytology specimen (Thinprep®)

Result Preview

Ordering Information

Product Cat. No. Size
Anyplex™ BRAF V600E Real-time Detection (V2.1) BR7100Y 50 rxns

If you are interested in finding more about this product,
please do not hesitate to contact us

Real-time : Real-time PCR
home > Products > IVD reagent > Others